West Pharmaceutical Services, Inc.

• WST Stock Price 24h change: -2.45%. From 255.16 USD to 248.92 USD. Factors include broader market volatility in the life sciences sector and continued digestion of the recent asset sale news to AbbVie.
• Technical analysis indicates a "neutral to bearish" outlook: the stock's RSI is around 52.8, suggesting it is neither overbought nor oversold. However, the short-term moving average remains below the long-term average, and the MACD reflects a bearish crossover, pointing toward near-term selling pressure despite a recent pivot bottom signal.
• West Pharmaceutical Services announced the global commercial availability of its Synchrony™ S1 prefillable syringe system at Pharmapack 2026, targeting the high-growth biologics and vaccine markets.
• AbbVie reached an agreement to acquire a West Pharmaceutical facility in Arizona for $175 million and purchase manufacturing rights for the SmartDose 3.5mL platform for $112.5 million.
• The company declared a quarterly dividend of $0.22 per share, with the ex-dividend date set for January 28, 2026.
• The global pharmaceutical packaging laminates market is projected to grow from $2.63 billion in 2025 to over $4.3 billion by 2034, driven by rising drug production and demand for high-barrier protection.
• Sharp announced a €20 million investment in European injectable packaging facilities to expand cold-chain storage and syringe assembly capacity, highlighting strong sector-wide demand for injectable drug delivery.

• WST Stock Price 24h change: +1.86%. From 250.50 USD to 255.16 USD.
The stock rebounded as investors sought value following a recent period of selling pressure and ahead of the company's participation in the Pharmapack 2026 conference.
• From a technical perspective, the stock is currently in an "oversold recovery" phase. The 14-day Relative Strength Index (RSI) recently touched 29.43, a clear oversold signal that triggered the latest bounce. While the 50-day moving average ($271.96) remains above the current price, indicating a short-term bearish trend, the upward revision in consensus EPS estimates suggests a potential fundamental floor is forming near current levels.
• West Pharmaceutical Services announced the global commercial availability of its Synchrony S1 prefillable syringe system at the Pharmapack 2026 event in Paris on January 20, aimed at meeting growing demand for biologics and vaccines.
• Upslope Capital Management reported exiting its position in WST as of January 19, 2026, citing better risk/reward opportunities elsewhere in the healthcare sector, which may have contributed to recent institutional selling.
• West Pharmaceutical signed an agreement on January 12 to sell the manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System to AbbVie for $112.5 million to streamline its portfolio.
• UnitedHealth CEO announced on January 21 that the insurer will rebate Affordable Care Act (ACA) profits to consumers, following shifts in federal health policy and increased regulatory scrutiny of insurance margins.
• The U.S. House Budget Committee held a hearing on January 21 titled "Reverse the Curse," examining skyrocketing healthcare costs and their impact on the nation's fiscal future, signaling potential legislative pressure on industry pricing.